Xenetic Biosciences

Historical price data

Xenetic Biosciences is a publicly-traded biopharma company developing adjunctive cancer therapies based on its DNase I platform, which targets neutrophil extracellular traps (NETs) to overcome resistance to standard treatments. The company is strategically positioned in the high-value oncology space, with a focus on pancreatic cancer and other solid tumors, and is backed by a team with significant industry experience. Its strategy involves advancing its lead candidate into clinical trials while leveraging key partnerships with research institutions and manufacturing organizations.

DNase I platform designed to degrade neutrophil extracellular traps (NETs) to overcome cancer treatment resistance and inhibit metastasis, intended for use as an adjunctive therapy with existing immunotherapies and chemotherapies.

1 drug in pipeline

Total raised: $15M

Xenetic is an early mover in the emerging field of NETs-targeting cancer therapies. Direct competition comes from a handful of private biotechs, while indirect competition includes all companies developing therapies to modulate the tumor microenvironment. Differentiation lies in its systemic enzyme approach and strategy to enhance existing treatments rather than replace them.